Establishment Labs Holdings has delivered a striking share price run in recent years, which puts a spotlight on a simple question for anyone looking at the stock today: how well do its current cash flows support that market value.
The issue now is whether the current US$70.75 share price is aligned with the intrinsic value implied by Establishment Labs Holdings' cash flows when viewed through a Discounted Cash Flow (DCF) lens.
If you are weighing whether Establishment Labs Holdings' recent 221.6% three year return still lines up with its cash flows, a focused stock screen is another useful starting point in your research, especially a set like 34 high quality undervalued stocks
The Discounted Cash Flow (DCF) model here uses a 2 Stage Free Cash Flow to Equity approach to translate Establishment Labs Holdings' projected cash generation into a per share value. Latest twelve month free cash flow sits at a loss of $28.6 million, so the whole framework leans on a sharp swing into positive territory rather than steady, mature cash generation.
Analyst and internal estimates in the model assume that Establishment Labs Holdings moves from that recent cash drain to growing positive free cash flow over the next decade, with rising annual amounts discounted back to today. Because the projections build in this recovery path and extend it over many years, the Discounted Cash Flow (DCF) output places the estimated intrinsic value meaningfully above the current $70.75 share price. The recent Q3 2026 update, with higher revenue and a narrower net loss alongside greater long term debt, helps explain why the market is still pricing the stock below what those cash flow estimates imply. Find out what Establishment Labs Holdings could be worth using our Discounted Cash Flow (DCF) estimate.
Narratives on Simply Wall St act as the missing link between Establishment Labs Holdings' cash flow based valuation puzzle and the assumptions that sit underneath it. They spell out what kind of growth, margins and earnings profile would need to hold for the stock to be worth materially more or materially less than today's price on the Community page. Each one ties a fair value to a clear storyline about Establishment Labs Holdings' potential catalysts and key risks, so you can watch over time which version of events appears to be unfolding.
One of the top narratives on Establishment Labs Holdings: 28% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"The main factor that has to go right is that Establishment Labs Holdings converts strong surgeon and patient demand into sustained operating leverage and structurally positive free cash flow..."
Discover why this Narrative puts Establishment Labs Holdings at 28% undervalued.
Cash flow models only tell part of the story. The people running Establishment Labs Holdings, and how their pay lines up with shareholder outcomes, can change the picture completely. See who runs Establishment Labs Holdings and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com